Skip to main content

Advertisement

SpringerLink
Log in

Serum Proteomic Analysis Identifies a Highly Sensitive and Specific Discriminatory Pattern in Stage 1 Breast Cancer

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Mass spectrometry (MS)-based profiling was used to determine whether ion fingerprints could distinguish women with stage 1 breast cancer from women without breast cancer.

Methods

The initial study population consisted of 310 subjects: 155 women with yearly negative breast examination and negative mammography findings for at least 4 years, and 155 women undergoing surgery for pathology-proven stage 1 invasive ductal carcinoma. High-resolution SELDI-TOF (surface-enhanced laser desorption ionization–time of flight) analysis was performed on serum obtained from blood samples collected before mammography in controls, and before surgery in patients with breast cancer. Samples were divided into a training (109 controls and 109 cancers) and blinded (46 controls and 46 cancers) testing set; each group had similar age demographics. In addition, an independent study set of 46 serum samples was analyzed 14 months after the initial study to validate the robustness of the classifier.

Results

A discriminatory profile consisting of seven ion peaks found in the training set, when applied to the blinded test set, achieved a sensitivity and specificity of 95.6% and 86.5%, respectively. This same seven-peak profile achieved a 96.5% sensitivity and 85.7% specificity, with correct identification of all of 17 T1a tumors when applied to the validation study set.

Conclusions

Mass spectrometry profiling of human serum generated a robust classifier composed of seven low-molecular-weight ions that yielded a highly sensitive and specific diagnostic procedure for the discrimination of women with stage 1 breast cancer compared with women without breast cancer in this research study set.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

FIG. 1.

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer. J Clin 2005;55:74–108

    Google Scholar 

  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer. J Clin 2006;56:106–30

    Google Scholar 

  3. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481–8

    Article  PubMed  CAS  Google Scholar 

  4. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA 2005;293:1245–56

    Article  PubMed  CAS  Google Scholar 

  5. Olsen AH, Njor SH, Vejborg I, et al. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. BMJ 2005;330:220

    Article  PubMed  Google Scholar 

  6. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003;361:1405–10

    Article  PubMed  Google Scholar 

  7. Wood WC, Anderson M, Lyles RH, et al. Can we select which patients with small breast cancers should receive adjuvant chemotherapy? Ann Surg 2002;235:859–62

    Article  PubMed  Google Scholar 

  8. Joensuu H, Pylkkanen L, Toikkanen S. Late mortality from pT1N0M0 breast carcinoma. Cancer 1999;85:2183–9

    Article  PubMed  CAS  Google Scholar 

  9. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845–67

    Article  PubMed  CAS  Google Scholar 

  10. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572–7

    Article  PubMed  CAS  Google Scholar 

  11. Zhang Z, Bast RC, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;4:5882–90

    Article  Google Scholar 

  12. Ornstein DK, Rayford W, Fusaro VA, et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol 2004;172:1302–5

    Article  PubMed  CAS  Google Scholar 

  13. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization MS. Clin Cancer Res 2004;10:860–8

    Article  PubMed  CAS  Google Scholar 

  14. Villanueva J, Philip J, Entenberg D, et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 2004;76:1560–70

    Article  PubMed  CAS  Google Scholar 

  15. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature 2003;425:905

    Article  PubMed  CAS  Google Scholar 

  16. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the LMW human serum proteome. Mol Cell Proteomics 2003;2:1096–103

    Article  PubMed  CAS  Google Scholar 

  17. Zhou M, Lucas DA, Chan KC, et al. An investigation into the human serum “interactome.” Electrophoresis 2004;25:1289–98

    Article  PubMed  CAS  Google Scholar 

  18. Johann D, McGuigan M, Tomov S, et al. Novel approaches to visualization and data mining reveals enrichment of diagnostic information in the low amplitude region of serum mass spectra from ovarian cancer patients. Dis Markers 2003–2004;19:197–207

    Google Scholar 

  19. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296–304

    PubMed  CAS  Google Scholar 

  20. Hu Y, Zhang S, Yu J, Liu J, Zhen S. SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast 2005;14:250–5

    Article  PubMed  Google Scholar 

  21. Li J, Orlandi R, White CN, et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 2006;52:771–2

    Article  Google Scholar 

  22. Mehta A, Ross S, Lowenthal MS, et al. Biomarker amplification by serum carrier protein binding. Dis Markers 2004;19:1–10

    Google Scholar 

  23. Lowenthal MS, Mehta AI, Frogale K, et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 2005;51:1933–45

    Article  PubMed  CAS  Google Scholar 

  24. Orel SG, Kay N, Reynolds C, Sullivan DC. BI-RADS categorization as a predictor of malignancy. Radiology 1999;211:845–50

    PubMed  CAS  Google Scholar 

  25. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer. J Clin 2006; 56:11–25

  26. Semmes OJ, Feng Z, Adam BL, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight MS for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102–12

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported in part by a from the Oncology Italy-USA Cooperation Program; federal funds from the National Cancer Institute, National Institutes of Health, under contract N01-CO-12400; the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.

The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.

Author information

Authors and Affiliations

  1. Department of Surgery, CRO–IRCCS, National Cancer Institute, Via Franco Gallini, 2, 33081, Aviano, (PN), Italy

    Claudio Belluco MD & Mario Lise MD

  2. Center for Applied Proteomics and Molecular Medicine, George Mason University, 10900 University Boulevard, 20110-2230, Manassas, Virginia, USA

    Emanuel F. Petricoin PhD & Lance A. Liotta MD

  3. Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani, 2, 35128, Padova, Italy

    Enzo Mammano MD, Donato Nitti MD, Cosimo Di Maggio MD & Mario Lise MD

  4. Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161, Rome, Italy

    Francesco Facchiano MD

  5. Clinical Proteomics Reference Laboratory, SAIC-Frederick, Inc. National Cancer Institute at Frederick, 22 Firstfield Road, Suite 180, Gaithersburg, Maryland, 20878, USA

    Sally Ross-Rucker MT, Chenwei Liu MS & Gordon Whiteley PhD

Authors
  1. Claudio Belluco MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emanuel F. Petricoin PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Enzo Mammano MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesco Facchiano MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sally Ross-Rucker MT
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Donato Nitti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Cosimo Di Maggio MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chenwei Liu MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mario Lise MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Lance A. Liotta MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Gordon Whiteley PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudio Belluco MD.

Additional information

Received Month 00, 2006; accepted Month 00, 2006; published online Month 00, 2007.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Belluco, C., Petricoin, E.F., Mammano, E. et al. Serum Proteomic Analysis Identifies a Highly Sensitive and Specific Discriminatory Pattern in Stage 1 Breast Cancer. Ann Surg Oncol 14, 2470–2476 (2007). https://doi.org/10.1245/s10434-007-9354-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-007-9354-3

Keywords

Search

Navigation